Viz.ai vs PathAI
Detailed side-by-side comparison to help you choose the right tool
Viz.ai
🔴DeveloperBusiness AI Solutions
AI-powered medical imaging platform that accelerates diagnosis and treatment of critical conditions
Was this helpful?
Starting Price
PaidPathAI
🟢No CodeAutomation & Workflows
AI-powered digital pathology platform providing FDA-cleared digital pathology image management, biomarker analysis, and enterprise workflow management for laboratories and biopharma companies.
Was this helpful?
Starting Price
Custom quoteFeature Comparison
Scroll horizontally to compare details.
Viz.ai - Pros & Cons
Pros
- ✓Improved diagnostic accuracy
- ✓24/7 monitoring
- ✓Data-driven insights
- ✓Cost reduction
Cons
- ✗Regulatory requirements
- ✗Privacy concerns
- ✗Cannot replace human doctors
PathAI - Pros & Cons
Pros
- ✓AISight Dx has FDA clearance for primary diagnosis in the United States and is CE-IVD marked for primary diagnosis in the EEA, UK, and Switzerland.
- ✓Designed for enterprise digital pathology workflows, including case management, image management, workflow tools, and access to AI applications from a central cloud-native platform.
- ✓Strong biopharma orientation, with products and services for biomarker discovery, histology assessment, drug development, and clinical trial endpoint standardization.
- ✓Large pathology data and expertise base, including a stated network of 450+ board-certified pathologists and 32.5M+ contributed annotations used to support algorithm development and validation.
- ✓Broad AI product menu covering areas such as PD-L1, HER2, ER, PR, Ki-67, MASH, inflammatory bowel disease, tumor cellularity, artifact detection, and tumor microenvironment analysis.
- ✓Recent large-scale partnerships, including Labcorp's expanded deployment of AISight Dx and MedStar Health's partnership to deploy AISight Dx and advanced AI applications.
Cons
- ✗Pricing is not public, so laboratories and sponsors must engage sales to understand total cost, implementation scope, and contract structure.
- ✗Several PathAI algorithms are explicitly described as Research Use Only in the United States and not for diagnostic procedures, which limits direct clinical diagnostic use cases.
- ✗Deployment depends on digital pathology infrastructure such as slide scanners, image workflows, validation processes, and lab change management.
- ✗AISight Dx scanner support is specific; PathAI lists FDA-cleared use with Hamamatsu NanoZoomer S360MD and Leica Aperio GT 450 DX scanners.
- ✗The platform is specialized for pathology organizations and biopharma teams, making it a poor fit for general healthcare AI automation, patient engagement, or routine clinical note-taking.
Not sure which to pick?
🎯 Take our quiz →🔒 Security & Compliance Comparison
Scroll horizontally to compare details.
🦞
🔔
Price Drop Alerts
Get notified when AI tools lower their prices
Get weekly AI agent tool insights
Comparisons, new tool launches, and expert recommendations delivered to your inbox.